Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 6
2010 1
2012 7
2013 5
2014 6
2016 2
2017 3
2018 1
2019 2
2020 2
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real-world cohorts.
Feld JJ, Forns X, Dylla DE, Kumada H, de Ledinghen V, Wei L, Brown RS Jr, Flisiak R, Lampertico P, Thabut D, Bondin M, Tatsch F, Burroughs M, Marcinak J, Zhang Z, Emmett A, Jacobson IM. Feld JJ, et al. Among authors: tatsch f. J Viral Hepat. 2022 Dec;29(12):1050-1061. doi: 10.1111/jvh.13738. Epub 2022 Oct 6. J Viral Hepat. 2022. PMID: 36036117 Free PMC article.
Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts.
Forns X, Feld JJ, Dylla DE, Pol S, Chayama K, Hou J, Heo J, Lampertico P, Brown A, Bondin M, Tatsch F, Burroughs M, Marcinak J, Zhang Z, Emmett A, Gordon SC, Jacobson IM. Forns X, et al. Among authors: tatsch f. Adv Ther. 2021 Jun;38(6):3409-3426. doi: 10.1007/s12325-021-01753-3. Epub 2021 May 22. Adv Ther. 2021. PMID: 34021887 Free PMC article.
Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
Dore GJ, Feld JJ, Thompson A, Martinello M, Muir AJ, Agarwal K, Müllhaupt B, Wedemeyer H, Lacombe K, Matthews GV, Schultz M, Klein M, Hezode C, Mercade GE, Kho D, Petoumenos K, Marks P, Tatsch F, Dos Santos AGP, Gane E; SMART-C Study Group. Dore GJ, et al. Among authors: tatsch f. J Hepatol. 2020 Mar;72(3):431-440. doi: 10.1016/j.jhep.2019.10.010. Epub 2019 Oct 23. J Hepatol. 2020. PMID: 31655134 Free article. Clinical Trial.
Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs.
Cheng Q, Cunningham EB, Shih S, Amin J, Bruneau J, Artenie AA, Powis J, Litwin AH, Cooper C, Dalgard O, Hellard M, Bruggmann P, Marks P, Lacombe K, Stedman C, Read P, Hajarizadeh B, Dunlop AJ, Conway B, Feld JJ, Dore GJ, Grebely J; SIMPLIFY and D3FEAT Study Groups. Cheng Q, et al. Value Health. 2023 Jun;26(6):883-892. doi: 10.1016/j.jval.2022.12.016. Epub 2023 Jan 13. Value Health. 2023. PMID: 36646278
HEPLA: A multicenter study on demographic and disease characteristics of patients with hepatitis C in Latin America.
Viola L, Marciano S, Colombato L, Coelho H, Cheinquer H, Bugarin G, Tatsch F, Carvalho-Filho RJ, Roblero JP, Varon A, Holguin J, Torres-Ibarra MR, Pérez-Ríos AM. Viola L, et al. Among authors: tatsch f. Ann Hepatol. 2020 Mar-Apr;19(2):161-165. doi: 10.1016/j.aohep.2019.09.006. Epub 2019 Oct 24. Ann Hepatol. 2020. PMID: 31718995 Free article.
Pharmacoeconomics applied to chronic hepatitis C.
Tatsch FF, Sette H Jr, Vianna D. Tatsch FF, et al. Braz J Infect Dis. 2006 Feb;10(1):51-4. doi: 10.1590/s1413-86702006000100010. Epub 2006 Jun 2. Braz J Infect Dis. 2006. PMID: 16767316 Review.
33 results